News
The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.
Pharmaceutical Technology on MSN10h
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRCPhase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback